Disulfiram for Cocaine Abuse in Buprenorphine Treatment

• ClinicalTrials.gov Identifier: NCT00913484
• Recruitment Status: Completed
• First Posted: June 4, 2009
• Last Update Posted: November 19, 2020
• Sponsor: Yale University
• Collaborator: National Institute on Drug Abuse (NIDA)
• Information provided by (Responsible Party): Yale University

Study Description

Brief Summary:

The investigators are proposing a placebo-controlled clinical trial to evaluate the efficacy and potential mechanisms of action of disulfiram (versus placebo) for treating cocaine abuse in subjects with concurrent opiate dependence and cocaine abuse or dependence maintained on buprenorphine/naloxone combination.

Condition or disease	Intervention/treatment	Phase
Cocaine Dependence; Opioid Dependency	Drug: Disulfiram; Drug: Placebo	Phase 2

Detailed Description:

The Specific Aims and hypotheses for the proposed study are as follows:

1. To compare the efficacy of disulfiram versus placebo for the treatment of buprenorphine maintained patients with concurrent opioid and cocaine dependence. Study hypothesis 1 is that disulfiram is superior to placebo.
2. To evaluate whether dopamine-B-hydroxylase (DBH) genotypes associated with high, intermediate or low enzyme activity predict responses to disulfiram treatment of cocaine use in buprenorphine treated subjects. Study hypothesis 2 is that disulfiram efficacy is higher in subjects with low DBH compared to subjects with high DBH.
3. To explore whether baseline measures of alcohol use predict response to disulfiram. Study Hypothesis 3 is that the effects of disulfiram on cocaine use are independent of the severity of baseline alcohol use.

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 177 participants
• Allocation: Randomized
• Intervention Model: Factorial Assignment
• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
• Primary Purpose: Treatment
• Official Title: Disulfiram for Cocaine Abuse in Buprenorphine Treatment
• Study Start Date: October 2000
• Actual Primary Completion Date: February 2004
• Actual Study Completion Date: February 2004

Arms and Interventions

Arm	Intervention/treatment
Experimental: Disulfiram; Disulfiram 250 mg per day	Drug: Disulfiram; Disulfiram 250 mg per day
Placebo Comparator: Placebo; Placebo	Drug: Placebo; Placebo daily

Outcome Measures

Primary Outcome Measures :

1. Cocaine abstinence [ Time Frame: 12 weeks ]

Secondary Outcome Measures :

1. Opioid abstinence [ Time Frame: 12 weeks ]

Eligibility Criteria

• Ages Eligible for Study: 18 Years to 45 Years (Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• English speaking adults ages 18 - 45.
• Meeting FDA criteria for agonist maintenance treatment and DSM-IV criteria for opioid dependence and cocaine dependence or abuse as assessed by SCID interview and documented by opioid positive and cocaine positive urine toxicology testing.
• Women of childbearing age will be included provided they agree to adequate contraception and to monthly pregnancy testing during the course of the study.

Exclusion Criteria:

• Current physiologic dependence on benzodiazepines or alcohol, unless first detoxified. Subjects who use/abuse alcohol will be included but will be cautioned about alcohol use during the study because of the possibility of an alcohol-disulfiram reaction.
• Use of the antibiotic agents metronidazole or clotrimazole, which have disulfiram-like effects in combination with alcohol.
• Presence of significant cardiovascular, renal, hepatic or neurologic illness. Subjects with markedly abnormal liver function tests (i.e., AST of ALT > 3X normal) will also be excluded.

• Presence of any of the following cardiovascular risk factors:

  • age > 45 years
  • history of cocaine-related chest pain
  • systolic blood pressure > 140 or diastolic blood pressure > 90
  • evidence of ischemia or past myocardial infarction on EKG
  • significant family history of risk (first degree relative with myocardial infarction prior to age 60)
  • elevated cholesterol (> 300 mg/dl), elevated LDL (> 170 mg/dl) or low HDL (< 20 mg/dl)
• Maintenance on methadone at doses greater than 30mg daily. Admittance to the study will only be offered to individuals who have been maintained on 30 mg of methadone or less daily for seven days prior to entering the study.
• Current suicide or homicide risk or current psychotic disorder.
• Inability to read or understand the symptom checklists.

Contacts and Locations

Locations

United States, Connecticut

The APT Foundation MRU

New Haven, Connecticut, United States, 06519

Yale University School of Medicine

New Haven, Connecticut, United States, 06519

Sponsors and Collaborators

Yale University

National Institute on Drug Abuse (NIDA)

Investigators

• Principal Investigator: Richard S. Schottenfeld, M.D.; Yale University

More Information

• Responsible Party: Yale University
• ClinicalTrials.gov Identifier: NCT00913484
• Other Study ID Numbers: 1R01DA012979 ( U.S. NIH Grant/Contract ); 1R01DA012979 ( U.S. NIH Grant/Contract )
• First Posted: June 4, 2009
• Last Update Posted: November 19, 2020
• Last Verified: November 2020

Keywords provided by Yale University:

Disulfiram; Buprenorphine; Cocaine dependence; Opioid dependence; Dopamine-Beta-Hydroxylase

Additional relevant MeSH terms:

Cocaine-Related Disorders; Substance-Related Disorders; Chemically-Induced Disorders; Mental Disorders; Disulfiram; Alcohol Deterrents; Acetaldehyde Dehydrogenase Inhibitors; Enzyme Inhibitors; Molecular Mechanisms of Pharmacological Action